Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial
Yui K, Koshiba M, Nakamura S, Kobayashi Y
Journal of clinical psychopharmacology · 77 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2012-02-25 · J Clin Psychopharmacol · vol. 32 · número 2 · págs. 200–206
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 109 citas · más que el 96% de estudios similares · 6.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 47 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Autism Spectrum Disorder Research · Child Nutrition and Feeding Issues
- Palabras clave
- autism spectrum disorder, arachidonic acid, docosahexaenoic acid, social dysfunction, social withdrawal, communication, signal transduction, transferrin, superoxide dismutase, antioxidants, plasma biomarkers, Aberrant Behavior Checklist, Social Responsiveness Scale
- MeSH
- humans, superoxide dismutase, docosahexaenoic acids, arachidonic acid, transferrin, treatment outcome, drug therapy, combination, double-blind method, child development disorders, pervasive, signal transduction, dose-response relationship, drug, social behavior disorders, adolescent, adult, child, female, male, young adult
4 autores
- Kunio Yui🇯🇵 · autor de correspondenciaAshiya University
- Mamiko Koshiba🇯🇵Tokyo University of Agriculture and Technology
- Shun Nakamura🇯🇵Tokyo University of Agriculture and Technology
- Yuji Kobayashi🇯🇵SRL (Japan)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Autism spectrum disorders are a neurodevelopmental disorders with reduced cortical functional connectivity relating to social cognition. Polyunsaturated fatty acids arachidonic acid (ARA) and docosahexaenoic acid (DHA) may have key role in brain network maturation. In particularly, ARA is important in signal transduction related to neuronal maturation. Supplementation with larger ARA doses added to DHA may therefore mitigate social impairment. In a 16-week, double-blind, randomized, placebo-controlled trial, we evaluated the efficacy of supplementation with large doses of ARA added to DHA (n = 7) or placebo (n = 6) in 13 participants (mean age, 14.6 [SD, 5.9] years). To examine underlying mechanisms underlying the effect of our supplementation regimen, we examined plasma levels of antioxidants transferrin and superoxide dismutase, which are useful markers of signal transduction. The outcome measures were the Social Responsiveness Scale and the Aberrant Behavior Checklist-Community. Repeated-measures analysis of variance revealed that our supplementation regimen significantly improved Aberrant Behavior Checklist-Community-measured social withdrawal and Social Responsiveness Scale-measured communication. Treatment effect sizes were more favorable for the treatment group compared with the placebo group (communication: treatment groups, 0.87 vs, placebo, 0.44; social withdrawal: treatment groups, 0.88, vs placebo, 0.54). There was a significant difference in the change in plasma transferrin levels and a trend toward a significant difference in the change in plasma superoxide dismutase levels between the 2 groups. This preliminary study suggests that supplementation with larger ARA doses added to DHA improves impaired social interaction in individuals with autism spectrum disorder by up-regulating signal transduction.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.